Alzheimer's disease (AD) pathology has been characterized, in part, by the self-assembly of the tau molecule into neurofibrillary tangles (NFT). While different post-translational modifications have been identified that accelerate tau aggregation, nitration at tyrosine residues prevents or slows tau filament formation in vitro. Of the five tyrosine residues within the molecule, nitration at the first tyrosine residue (Tyr 18) results in a profound inhibition of filament self-assembly. To determine whether nitration at Tyr 18 occurs in AD pathology, monoclonal antibodies were raised against a synthetic tau peptide nitrated at Tyr 18. A clone, termed Tau-nY18, reacts specifically with tau proteins nitrated at Tyr 18 and fails to cross-react with other nitrated tyrosine residues spanning the length of the molecule or with other proteins known to be nitrated in neurodegenerative diseases. In situ, Tau-nY18 sparsely labels the neuronal pathological hallmarks of the disease, including NFT and dystrophic neurites. Surprisingly however, Tau-nY18 robustly labels nitrated tau within activated, GFAP positive astrocytes intimately associated with amyloid plaques. Furthermore, this antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and agematched controls. Collectively, these findings suggest that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder pathologically characterized by the formation of neurofibrillary tangles (NFT) and amyloid plaques, in which the major protein constituents are aggregated tau proteins and beta-amyloid peptides (Aβ), respectively (Glenner and Wong, 1984; Grundke-Iqbal et al., 1986a; Kosik et al., 1986; Goedert et al., 1988) . Tau is a microtubuleassociated protein (MAP) expressed within neurons and various glial cell types, including astrocytes and oligodendrocytes, although at much lower levels than neurons (Papasozomenos and Binder, 1987; Shin et al., 1991; Couchie et al., 1992; LoPresti et al., 1995) . Under normal physiological conditions, tau is a highly soluble protein (Schweers et al., 1994) primarily involved in promoting microtubule assembly and stability through the specific interaction between the tau tandem repeat region and tubulin proteins (Lee et al., 1988) . While these repeats localize to the C-terminal one-third region of the molecule and are highly conserved among different species, the N-terminal region has the greatest variability. For example, tau from human and non-human primates contains a unique sequence of 10 amino acids, which includes a tyrosine residue at position 18 (Tyr 18) not found in other species (Himmler et al., 1989; Alonso et al., 1995) .
Tyrosine residues have been identified as specific sites for oxidative and/or nitrative modifications following exposure to peroxynitrite (Beckman et al., 1994a; Ischiropoulos and al-Mehdi, 1995; Beckman, 1996a,b) . Although a limited number of proteins appear to be susceptible to peroxynitrite-mediated nitration (Giasson et al., 2000; Horiguchi et al., 2003) , tau is selectively vulnerable at tyrosine residues within the most N-terminal region of the molecule (Tyr 18 and 29) . Notably, nitration at Tyr 18 largely prevents or slows tau filament self-assembly, an inhibitory mechanism not observed by either oxidation or pseudophosphorylation at the same tyrosine site (Reynolds et al., 2005b,a) .
Although nitration prevents tau filament formation in vitro, nitrated proteins are selectively localized to tau deposits in various neurodegenerative diseases, as detected by different nitro-tyrosine antibodies (Giasson et al., 2000; Souza et al., 2000; Horiguchi et al., 2003) . However, these antibodies lack protein and site-specificity, a limitation that prevents studying site-directed modifications during disease progression. To examine site-directed tyrosine nitration, we previously developed the monoclonal antibody Tau-nY29, an immunological probe that reacts specifically with tau nitrated at Tyr 29 (Reynolds et al., 2006) . Tau-nY29 labels a subset of soluble tau and insoluble paired helical filaments (PHF-tau) purified from pathologically severe AD brains (Braak stages V and VI), but fails to label tau from non-demented Neurobiology of Disease 31 (2008) 198-208 
